Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
28.86
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Oct 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
10,546,357
Open
28.86
Bid (Size)
29.16 (3)
Ask (Size)
29.18 (7)
Prev. Close
28.86
Today's Range
28.86 - 28.86
52wk Range
25.20 - 31.54
Shares Outstanding
5,606,688,356
Dividend Yield
5.68%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Pfizer Q3 Earnings: Revenue And Profit Beat On Heightened Demand For Paxlovid, Expects $10 Billion In 2024 Revenue From COVID Products
Today 8:02 EDT
Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, Comirnaty, and Seagen contributions.
Via
Benzinga
Exposures
COVID-19
US Stocks Likely To Open Weaker As Investors Eye Alphabet, AMD And Pfizer Earnings: Expert Says Won't Be 'Surprised' If Earnings Exceed Wall Street Expectations
Today 7:42 EDT
U.S. stocks could see a weak opening on Tuesday after the averages registered a mixed last week.
Via
Benzinga
Performance
YTD
-2.93%
-2.93%
1 Month
-0.28%
-0.28%
3 Month
-6.05%
-6.05%
6 Month
+12.56%
+12.56%
1 Year
-5.53%
-5.53%
More News
Read More
Pfizer Earnings Top Q3 Views; Pharma Giant Guides Higher
Today 7:05 EDT
Via
Investor's Business Daily
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
Today 6:45 EDT
From
Pfizer Inc.
Via
Business Wire
Key Takeaways From Pfizer Analyst Ratings
October 23, 2024
Via
Benzinga
A Closer Look at Pfizer's Options Market Dynamics
October 23, 2024
Via
Benzinga
Dow Surges Over 250 Points Ahead Of Alphabet, Pfizer Earnings: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone
Today 3:09 EDT
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Pfizer, Alphabet And 3 Stocks To Watch Heading Into Tuesday
Today 2:01 EDT
Via
Benzinga
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
October 28, 2024
Via
Benzinga
What Lies In Store For Healthcare ETFs In Q3 Earnings?
October 27, 2024
Via
Talk Markets
Topics
ETFs
These 7 Blunt Words Just Opened a Can of Worms For Pfizer's Stock
October 27, 2024
Via
The Motley Fool
3 Magnificent S&P 500 Dividend Stocks Down 43%, 20%, and 53% to Buy and Hold Forever
October 26, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
3 Spooky Signs That You're About to Lose Your Money on a Healthcare Stock Investment
October 26, 2024
Via
The Motley Fool
Pfizer, Live Nation Entertainment And More On CNBC's 'Final Trades'
October 25, 2024
Via
Benzinga
Got $1,000? 2 Healthcare Stocks to Buy and Hold Forever.
October 25, 2024
Via
The Motley Fool
3 Sweet Dividend Stocks to Treat Your Portfolio With This Halloween
October 25, 2024
Via
The Motley Fool
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
October 24, 2024
Via
Benzinga
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
October 24, 2024
Via
Benzinga
5 High-Yield Dividend Stocks to Buy Without Hesitation
October 24, 2024
Via
The Motley Fool
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
October 23, 2024
Via
Benzinga
Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
October 23, 2024
From
Pfizer Inc.
Via
Business Wire
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
October 23, 2024
Via
Benzinga
Exposures
Product Safety
The Best Pharmaceutical Stock to Invest $1,000 in Right Now
October 23, 2024
Via
The Motley Fool
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
October 22, 2024
From
Pfizer Inc.
Via
Business Wire
Activist Investor Starboard Slams Pfizer for Underperforming R&D And Overpaying for Acquisitions
October 22, 2024
Via
Benzinga
Exposures
COVID-19
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.